Clinical Trials Directory

Trials / Unknown

UnknownNCT01567774

Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity

Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
University of Roma La Sapienza · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients with coronary artery disease (CAD) are often treated with dual antiplatelet therapy (DAT), including aspirin and clopidogrel, to prevent from recurrent atherothrombotic events. Levels of platelet reactivity in patients on DAT can be influenced by concomitant treatment with medications that inhibit the CYP3A4 system involved in the activation of clopidogrel. Atorvastatin and simvastatin are metabolized by CYP3A4 \[Clin pharmacokinetic 2002; 41: 343-70\], whereas the cytochrome P450 mediated metabolism of rosuvastatin appears to be minimal and principally mediated by the 2C9 isoenzyme, with little involvement of CYP3A4 \[Clin Ther 2003; 25: 2822-5.\]. Previous studies comparing atorvastatin versus rosuvastatin by means of ex vivo platelet function tests have yielded conflicting results.

Detailed description

At least 1 month after starting DAT (clopidogrel 75 mg and aspirin 100 mg), patients will receive randomly atorvastatin (20 mg day, N=50) or rosuvastatin (10 mg bid, N=50) for 30 days (until T-1). At this time-point, there will be a wash-out period of 15 days after the first treatment with atorvastatin or rosuvastatin in order to avoid any carry-over effect. Afterwards, a cross-over will be performed, and patients will be switched to the other drug which will be continued for further 30 days (until T-2).

Conditions

Interventions

TypeNameDescription
DRUGAtorvastatinos, 20 mg, once per day, for 30 days
DRUGRosuvastatinos, 10 mg, once per day, for 30 days

Timeline

Start date
2012-04-01
Primary completion
2014-03-01
Completion
2015-06-01
First posted
2012-03-30
Last updated
2013-05-06

Locations

2 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT01567774. Inclusion in this directory is not an endorsement.